Eversept Partners LP trimmed its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) by 23.3% in the fourth quarter, Holdings Channel reports. The fund owned 127,561 shares of the company’s stock after selling 38,830 shares during the quarter. Eversept Partners LP’s holdings in Structure Therapeutics were worth $8,872,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of GPCR. Morgan Stanley boosted its holdings in Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after acquiring an additional 1,510,093 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Structure Therapeutics by 477.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock valued at $116,228,000 after acquiring an additional 1,381,745 shares during the period. Avoro Capital Advisors LLC boosted its holdings in Structure Therapeutics by 21.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after acquiring an additional 1,150,000 shares during the period. Capitolis Liquid Global Markets LLC bought a new stake in Structure Therapeutics during the fourth quarter valued at about $61,086,000. Finally, Deutsche Bank AG bought a new stake in Structure Therapeutics during the fourth quarter valued at about $58,503,000. 91.78% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. William Blair restated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Tuesday, April 21st. Wolfe Research assumed coverage on shares of Structure Therapeutics in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Finally, HC Wainwright reduced their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $106.75.
Structure Therapeutics Stock Up 4.9%
Shares of GPCR opened at $45.00 on Thursday. The stock has a market cap of $3.20 billion, a price-to-earnings ratio of -51.72 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $15.80 and a 12 month high of $94.90. The company has a 50-day moving average price of $43.09 and a two-hundred day moving average price of $57.53.
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. Equities research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.
Structure Therapeutics Profile
Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.
The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.
Further Reading
- Five stocks we like better than Structure Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report).
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
